

## Supplementary Online Content

Yu-Wai-Man C, Tagalakis AD, Meng J, et al. Genotype-phenotype associations of *IL6* and *PRG4* with conjunctival fibrosis after glaucoma surgery. *JAMA Ophthalmol*. Published online September 21, 2017. doi:10.1001/jamaophthalmol.2017.3407

**eTable 1.** Patient Demographics

**eTable 2.** Fibrotic and Nonfibrotic Fibroblast Cell Lines

**eTable 3.** Correlation of *IL6* and *PRG4* Gene Expression With Clinical Phenotype

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1.** Patient Demographics

	<b>Fibrotic (n = 28)</b>	<b>Non-Fibrotic (n = 14)</b>
Gender		
Male (%)	12 (43%)	10 (71%)
Female (%)	16 (57%)	4 (29%)
Age (Years)		
Mean ± SEM	43.8 ± 3.6	47.7 ± 6.9
Eye		
Left (%)	11 (39%)	8 (57%)
Right (%)	17 (61%)	6 (43%)
Ethnicity		
White (%)	22 (79%)	9 (64%)
Asian (%)	4 (14%)	4 (29%)
Afro-Caribbean (%)	2 (7%)	1 (7%)
Lens Status		
Phakic (%)	16 (57%)	8 (57%)
Pseudophakia (%)	11 (39%)	5 (36%)
Aphakia (%)	1 (4%)	1 (7%)
Glaucoma Type		
POAG (%)	12 (43%)	7 (50%)
PACG (%)	1 (4%)	1 (7%)
JOAG (%)	2 (7%)	0
Congenital (%)	6 (21%)	2 (14%)
Secondary (%)	7 (25%)	4 (29%)
Previous Surgery		
Trabeculectomy (%)	13 (47%)	-
Tube (%)	4 (14%)	-
Multiple surgeries (%)	11 (39%)	-
Diode laser (%)	8 (29%)	-

**eTable 2.** Fibrotic and Nonfibrotic Fibroblast Cell Lines

<b>Cell line</b>	<b>Patient age</b>	<b>Gender</b>	<b>Treatment</b>
FF3	63	Female	1 previous surgery (Trabeculectomy) Betablocker/ prostaglandin analogue/ carbonic anhydrase inhibitor/ alpha agonist eye drops
FF13	51	Female	1 previous surgery (Tube surgery) No eye drops
FF14	22	Male	2 previous surgeries (Trabeculectomy, Tube surgery) Betablocker/ prostaglandin analogue/ carbonic anhydrase inhibitor eye drops
FF15	65	Male	1 previous surgery (Trabeculectomy) Betablocker/ prostaglandin analogue/ carbonic anhydrase inhibitor/ pilocarpine eye drops
FF16	18	Female	3 previous surgeries (Trabeculectomy, 2 Tube surgeries) Prostaglandin analogue eye drops
FF17	38	Male	1 previous surgery (Trabeculectomy) Betablocker/ prostaglandin analogue/ carbonic anhydrase inhibitor/ alpha agonist/ pilocarpine eye drops
NF1	72	Female	No previous surgery Betablocker/ prostaglandin analogue/ carbonic anhydrase inhibitor eye drops
NF4	24	Male	No previous surgery Betablocker/ prostaglandin analogue/ carbonic anhydrase inhibitor/ alpha agonist/ pilocarpine eye drops
NF7	75	Male	No previous surgery Betablocker/ carbonic anhydrase inhibitor/ alpha agonist eye drops
NF8	20	Male	No previous surgery Betablocker/ prostaglandin analogue/ carbonic anhydrase inhibitor/ alpha agonist eye drops

© 2017 American Medical Association. All rights reserved.

**eTable 3.** Correlation of *IL6* and *PRG4* Gene Expression With Clinical Phenotype

	<b>Spearman correlation r</b>	<b>P value</b>		<b>Spearman correlation r</b>	<b>P value</b>
<i>IL-6</i> gene vs Central area	.49	.150	<i>PRG4</i> gene vs Central area	-.06	.383
<i>IL-6</i> gene vs Maximal area	.49	.150	<i>PRG4</i> gene vs Maximal area	-.06	.383
<i>IL-6</i> gene vs Bleb height	.49	.150	<i>PRG4</i> gene vs Bleb height	-.06	.383
<i>IL-6</i> gene vs Vascularity	.21	.367	<i>PRG4</i> gene vs Vascularity	-.09	.408
<i>IL-6</i> gene vs No. of previous operations	.94	<.001	<i>PRG4</i> gene vs No. of previous operations	-.72	.005
<i>IL-6</i> gene vs Age	-.50	.072	<i>PRG4</i> gene vs Age	.10	.393
<i>IL-6</i> gene vs IOP	-.22	.265	<i>PRG4</i> gene vs IOP	.34	.167
<i>IL-6</i> gene vs logMAR VA	.64	.026	<i>PRG4</i> gene vs logMAR VA	-.62	.026
<i>IL-6</i> gene vs C/D area	.38	.143	<i>PRG4</i> gene vs C/D area	-.08	.293
<i>IL-6</i> gene vs No. of eye drops	-.36	.131	<i>PRG4</i> gene vs No. of eye drops	.27	.225